EMA Approves Pfizer's COVID-19 Treatment for Severe Respiratory Disease

Summary

European Medicines Agency (EMA) has approved a new proposal for the use of a COVID-19 treatment, developed by pharmaceutical company Pfizer (NYSE: PFE), in patients with severe respiratory disease. The approval is based on a recent clinical trial that showed significant improvements in patient outcomes.